skip to main content
Idioma:

Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial

Caliman-Fontes, Ana Teresa ; Leal, Gustavo C. ; Correia-Melo, Fernanda S. ; Paixao, Camilla S. ; Carvalho, Michelle S. ; Jesus-Nunes, Ana Paula ; Vieira, Flavia ; Magnavita, Guilherme ; Bandeira, Igor D. ; Mello, Rodrigo P. ; Beanes, Graziele ; Silva, Samantha S. ; Echegaray, Mariana ; Carvalho, Lucas P. ; Machado, Paulo ; Sampaio, Aline S. ; Cardoso, Taiane de A. ; Kapczinski, Flávio ; Lacerda, Acioly L. T. ; Quarantini, Lucas C.

SciELO journals 2023

Texto completo disponível

Citações Citado por
  • Título:
    Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial
  • Autor: Caliman-Fontes, Ana Teresa ; Leal, Gustavo C. ; Correia-Melo, Fernanda S. ; Paixao, Camilla S. ; Carvalho, Michelle S. ; Jesus-Nunes, Ana Paula ; Vieira, Flavia ; Magnavita, Guilherme ; Bandeira, Igor D. ; Mello, Rodrigo P. ; Beanes, Graziele ; Silva, Samantha S. ; Echegaray, Mariana ; Carvalho, Lucas P. ; Machado, Paulo ; Sampaio, Aline S. ; Cardoso, Taiane de A. ; Kapczinski, Flávio ; Lacerda, Acioly L. T. ; Quarantini, Lucas C.
  • Assuntos: FOS: Clinical medicine ; Psychiatry (incl. Psychotherapy)
  • Notas: 10.47626/2237-6089-2021-0298
    RelationTypeNote: IsSupplementTo -- 10.47626/2237-6089-2021-0298
  • Descrição: Abstract Objectives Evidence suggests that ketamine’s influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD). Methods Participants (n = 53) are from a randomized, double-blind clinical trial comparing the efficacy of single-dose ketamine (0.5mg/kg, n = 27) and esketamine (0.25mg/kg, n = 26) in TRD. Depression severity was assessed before and 24 hours, 72 hours, and 7 days after the intervention, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Blood samples were collected before infusion, 24 hours, and 7 days afterwards. Results There were no significant changes in BDNF levels at post-infusion evaluation points, and no difference in BDNF levels comparing ketamine and esketamine. Both drugs exhibited similar therapeutic effect. There was no association between BDNF levels and response to treatment or severity of depressive symptoms. Conclusion There was no significant treatment impact on BDNF serum levels – neither with ketamine nor esketamine – despite therapeutic response. These results suggest that ketamine or esketamine intervention for TRD has no impact on BDNF levels measured at 24 hours and 7 days after the infusion. This clinical trial is registered on the Japan Primary Registries Network: UMIN000032355.
  • Editor: SciELO journals
  • Data de criação/publicação: 2023
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  8 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.